Sunday, January 31, 2010
(abstract) Aberrant DNA methylation in contrast with mutations. 2009; Cancer Science
Note: technical/short abstract
Saturday, January 30, 2010
videos: The Chemotherapy Foundation Symposium
Note: there are some key videos (free to view) from a variety of subjects
Meeting Archives
Chemotherapy Foundation Symposium XXVI
November 4 -8, 2008
Marriott Marquis Hotel , New York , NY
November 4 -8, 2008
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Friday, January 29, 2010
2007 Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites
reference: Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 9043
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? -- The Oncologist
"Despite the very strong preclinical evidence for an obligatory role of VEGF in the formation of malignant ascites and for a possible therapeutic efficacy of anti-VEGF therapies in the setting of malignant effusions, there are currently no reports from clinical studies addressing this point in cancer patients..........To date, only very few patients with malignant ascites have received i.p. bevacizumab and, therefore, this route of administration as well as this particular patient population need to be examined stringently regarding the safety of the treatment. However, we believe that i.p. application might be the route of choice in this particular setting."
Immunotherapy of Cancer: Key Findings and Commentary on the Third Tegernsee Conference -2009- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma -- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
Patient Safety: note the adverse effects
"In the reviewed trial, serious adverse events and National Cancer Institute Common Terminology Criteria for Adverse Events grade
3 adverse events were reported more frequently in
bevacizumab-treated patients (31% versus 19% and 63% versus
47%, respectively). The most common bevacizumab-related
toxicities were bleeding/hemorrhage, hypertension,
proteinuria, and venous or arterial thromboembolic events."
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside -- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
Preventing Future Cancers by Testing Women With Ovarian Cancer for BRCA Mutations -- University of British Columbia/MD Anderson
"BRCA testing of women with ovarian cancer based on personal/family history of cancer or Ashkenazi Jewish ancestry is a cost-effective strategy to prevent future breast and ovarian cancers among FDRs (first degree relatives). More inclusive testing strategies prevent additional cancer cases but at significant cost."
GenSpera Announces First Cancer Patient Treated With G-202 In Phase I Trial
WARNING: this information is from a media article and gives virtually no information, so cautions. This obviously is not intended to discredit Johns Hopkins/Wisconsin Cancer Center, but the lack of information in the article.
"Patients interested in enrolling in the G-202 trial may contact the University of Wisconsin Carbone Cancer Center Connect line at (800) 622-8922. Patients who want to be evaluated for eligibility for this study at Johns Hopkins should call 410-955-8964, option #2. "
Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes
Note: highly technical paper comparing serous, clear cell and endometrioid ovarian cancer cells type/endometriosis/Interleukins (in research)
Patient Advocate Foundation :: 1-800-532-5274
help for solving insurance and access problems (U.S.):
Patient Advocate Foundation :: 1-800-532-5274
Subscribe to:
Posts
(
Atom
)
